Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Grifols ( (ES:GRF) ) has shared an announcement.
Grifols, S.A. has announced its Ordinary General Shareholders’ Meeting scheduled for June 2025, where key agenda items include the examination and approval of financial statements, the appointment of Deloitte Auditores, S.L. for sustainability verification, and changes to the Board of Directors. The meeting will also address the approval of a new remuneration policy and a 2025 Share Incentive Plan, alongside authorizations for treasury share acquisitions and potential extraordinary meetings, reflecting the company’s ongoing efforts to enhance governance and shareholder engagement.
More about Grifols
Grifols, S.A. is a global healthcare company primarily engaged in the production of plasma-derived medicines and transfusion medicine. The company focuses on improving the health and well-being of people around the world through innovative solutions in the biopharmaceutical industry.
YTD Price Performance: -9.26%
Average Trading Volume: 316,924
Technical Sentiment Signal: Strong Buy
Current Market Cap: €5.11B
For a thorough assessment of GRF stock, go to TipRanks’ Stock Analysis page.